Answers are grounded in this paper and cite their sources.
Reveals distinct cardiovascular complication risks across noradrenergic and adrenergic phenotypes, highlighting phenotype-specific heart damage.
We found a 28% incidence of cardiovascular complications in a consecutive group of patients with pheochromocytoma and paraganglioma. Patients presenting with a noradrenergic phenotype have a higher incidence of atherosclerotic complications, while the adrenergic phenotype is associated with a higher incidence of acute myocardial damage due to takotsubo-like cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Petrák et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: